中草药

天然萜类产物干预PI3K/Akt信号通路治疗肺癌的作用机制研究进展

PDF下载

中草药 | 综述 2026,57(10): 4038-4050

收起

中草药 |综述 2026 , 57 (10) : 4038 -4050

天然萜类产物干预PI3K/Akt信号通路治疗肺癌的作用机制研究进展

全屏

赵瑞^1,2,3, 郝二伟^1,2,3, 张帆^1,2,3

作者信息

通讯作者:

郝二伟

作者简介:

赵瑞: 赵瑞,男,硕士研究生,研究方向为中药药效筛选。E-mail:1162666252@qq.com

Research progress on mechanism of natural terpenoids interfering with PI3K/Akt signaling pathway in treatment of lung cancer

ZHAO Rui, HAO Erwei, ZHANG Fan

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.10.031

文章导航

摘要

收起

肺癌目前主要以手术、化疗和靶向治疗作为治疗肺癌的主要办法，其中靶向治疗有望成为治疗肺癌最有效的方法。随着对推动肺癌发展的分子变化和基因组生物标志物的理解加深，发现磷脂酰肌醇3-激酶（phosphatidylinositol-3-kinase，PI3K）/蛋白激酶B（protein kinase B，Akt）通路是影响肺癌发生发展的重要一环。该通路是细胞中广泛存在的重要信号通路，激活会导致癌症的多种特征，包括获得性生长信号自主性、细胞凋亡抑制、持续血管新生、组织侵袭和转移增加及对抗生长信号不敏感等，从而调控癌症的进程。天然萜类产物可通过抑制PI3K/Akt通路发挥抗肺癌活性，然而对于此类化合物的研究多停留在体外及体内研究层面，缺乏对这些数据的系统梳理与总结。基于这些现状，就天然萜类产物通过PI3K/Akt信号通路调控肺癌进展的思路进行总结，为探索新型靶向药物和临床治疗肺癌提供相关的理论依据。

关键词

萜类 / 肺癌 / PI3K/Akt信号通路 / 天然药物 / 凋亡

Abstract

收起

At present, lung cancer is mainly treated by surgery, chemotherapy and targeted therapy, among which targeted therapy is expected to be the most effective method. With the increasing understanding of molecular changes and genomic biomarkers that promote the development of lung cancer, it has been found that the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) pathway is an important part of the development of lung cancer. This pathway is an important signaling pathway that is widely present in cells. Activation can lead to a variety of characteristics of cancer, including acquired growth signal autonomy, apoptosis inhibition, continuous angiogenesis, increased tissue invasion and metastasis, and insensitivity to anti-growth signals, thereby regulating the process of cancer. Natural terpenoids can exert anti-lung cancer activity by inhibiting PI3K/Akt pathway. However, the research on such compounds mostly stays at the level of in vitro and in vivo research, and there is a lack of systematic review and summary of these data. Based on these current situations, this review summarizes the current understanding of natural terpenoids in regulating lung cancer progression through the PI3K/Akt signaling pathway, aiming to explore new targeted drugs and provide relevant theoretical basis for clinical treatment of lung cancer.

Key words

terpenoids / lung cancer / PI3K/Akt signaling pathways / natural drugs / apoptosis

引用本文

赵瑞, 郝二伟, 张帆. 天然萜类产物干预PI3K/Akt信号通路治疗肺癌的作用机制研究进展. 中草药, 2026 , 57 (10) : 4038 -4050 . DOI: 10.7501/j.issn.0253-2670.2026.10.031

ZHAO Rui, HAO Erwei, ZHANG Fan. Research progress on mechanism of natural terpenoids interfering with PI3K/Akt signaling pathway in treatment of lung cancer[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (10) : 4038 -4050 . DOI: 10.7501/j.issn.0253-2670.2026.10.031

基金

收起

2025年八桂学者项目 (桂人才办[2025]31号)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

Thai A A, Solomon B J, Sequist L V, et al. Lung cancer [J]. Lancet, 2021, 398(10299): 535-554.
肖祥, 吴宣諭, 韩洁榕, 等.“肺与大肠相表里”视角下探索肠道菌群与肺癌因果关联及潜在干预中药预测[J]. 中草药, 2024, 55(12): 4108-4120.
Chen H S, Xu J, Liu W B, et al. The epidemiology, etiology, and future prophylactic options for cancers in Mainland China [J]. Front Oncol, 2025, 15: 1579378.
Howlader N, Forjaz G, Mooradian M J, et al. The effect of advances in lung-cancer treatment on population mortality [J]. N Engl J Med, 2020, 383(7): 640-649.
Sezer H F. Current surgical perspective on the prognosis of small-cell lung cancer [J]. Diagnostics, 2025, 15(21): 2704.
Wang R, Qu Z, Lv Y, et al. Important roles of PI3K/Akt signaling pathway and relevant inhibitors in prostate cancer progression [J]. Cancer Med, 2024, 13(21): e70354.
Tan A C. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC) [J]. Thorac Cancer, 2020, 11(3): 511-518.
Wali A F, Talath S, El Tanani M, et al. PI3K/Akt/mTOR pathway in breast cancer pathogenesis and therapy: Insights into phytochemical-based therapeutics [J]. Nutr Cancer, 2025, 77(9): 938-958.
闫靖楠, 宋忠阳, 祁亚锋, 等. 中药调控肿瘤免疫微环境的作用及机制研究进展[J]. 中草药, 2025, 56(17): 6477-6492.
Luo H, Vong C T, Chen H B, et al. Naturally occurring anti-cancer compounds: Shining from Chinese herbal medicine [J]. Chin Med, 2019, 14(1): 48.
Kamran S, Sinniah A, Abdulghani M A M, et al. Therapeutic potential of certain terpenoids as anticancer agents: A scoping review [J]. Cancers, 2022, 14(5): 1100.
Mafi S, Mansoori B, Taeb S, et al. mTOR-mediated regulation of immune responses in cancer and tumor microenvironment [J]. Front Immunol, 2022, 12: 774103.
Tewari D, Patni P, Bishayee A, et al. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy [J]. Semin Cancer Biol, 2022, 80: 1-17.
Baghery Saghchy Khorasani A, Pourbagheri-Sigaroodi A, Pirsalehi A, et al. The PI3K/Akt/mTOR signaling pathway in gastric cancer From oncogenic variations to the possibilities for pharmacologic interventions [J]. Eur J Pharmacol, 2021, 898: 173983.
Mazloumi Gavgani F, Smith Arnesen V, Jacobsen R G, et al. Class I phosphoinositide 3-kinase PIK3CA/p110α and PIK3CB/p110β isoforms in endometrial cancer [J]. Int J Mol Sci, 2018, 19(12): 3931.
Alobid S. Targeting the PI3K/Akt/mTOR signaling pathway in prostate cancer: Molecular dysregulation, therapeutic advances, and future directions [J]. Saudi Pharm, 2026, 34(1): 2.
Sanaei M J, Razi S, Pourbagheri-Sigaroodi A, et al. The PI3K/Akt/mTOR pathway in lung cancer oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles [J]. Transl Oncol, 2022, 18: 101364.
Rice S J, Liu X, Wang H G, et al. EGFR mutations and Akt phosphorylation are markers for sensitivity to combined MCL-1 and Bcl-2/xL inhibition in non-small cell lung cancer [J]. PLoS One, 2019, 14(5): e0217657.
Nazari N, Jafari F, Ghalamfarsa G, et al. The emerging role of microRNA in regulating the mTOR signaling pathway in immune and inflammatory responses [J]. Immunol Cell Biol, 2021, 99(8): 814-832.
Shi X, Wang J J, Lei Y, et al. Research progress on the PI3K/Akt signaling pathway in gynecological cancer (Review) [J]. Mol Med Report, 2019, 19(6): 4529-4535.
Li X M, Wu C J, Chen N C, et al. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma [J]. Oncotarget, 2016, 7(22): 33440-33450.
Papadimitrakopoulou V. Development of PI3K/Akt/ mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer [J]. J Thorac Oncol, 2012, 7(8): 1315-1326.
胡志英, 朱新江, 陈舒晨, 等. 非小细胞肺癌PI3K/ Akt/mTOR信号通路的研究现状与进展[J]. 癌症进展, 2018, 16(6): 671-674.
摆惠芹, 加孜那·托哈依. PIK/Akt/mTOR信号通路在肺腺癌不同EGFR突变状态中的临床相关研究与预测价值[J]. 新疆医科大学学报, 2024, 47(3): 308-313.
Xu L, Wang Q, Wu L. Adenocarcinoma of the lung with EGFR gene mutation and subsequent resistance mechanisms exploration: Case report [J]. OncoTargets Ther, 2017, 10: 4517-4525.
Zhang Y, Han K. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/Akt/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma [J]. J Can Res Ther, 2019, 15(4): 914.
Wang X M, Xu W F, Zhu C Y, et al. PRMT7 inhibits the proliferation and migration of gastric cancer cells by suppressing the PI3K/Akt pathway via PTEN [J]. J Cancer, 2023, 14(15): 2833-2844.
Alfieri R, Giovannetti E, Bonelli M, et al. New treatment opportunities in phosphatase and tensin homolog (PTEN)-deficient tumors: Focus on PTEN/focal adhesion kinase pathway [J]. Front Oncol, 2017, 7: 170.
邓世超. 不同信号通路在非小细胞肺癌中的预测价值研究[D]. 长沙: 中南大学, 2022.
Ligresti G, Militello L, Steelman L S, et al. PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches [J]. Cell Cycle, 2009, 8(9): 1352-1358.
He Y, Sun M M, Zhang G G, et al. Targeting PI3K/Akt signal transduction for cancer therapy [J]. Signal Transduct Target Ther, 2021, 6: 425.
Thorpe L M, Yuzugullu H, Zhao J J. PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting [J]. Nat Rev Cancer, 2015, 15(1): 7-24.
Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA mutations and copy number gains in human lung cancers [J]. Cancer Res, 2008, 68(17): 6913-6921.
Liao S X, Sun P P, Gu Y H, et al. Autophagy and pulmonary disease [J]. Ther Adv Respir Dis, 2019, 13: 1753466619890538.
Poillet-Perez L, Sharp D W, Yang Y, et al. Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response [J]. Nat Cancer, 2020, 1(9): 923-934.
Wu Z N, Li W, Tang Q, et al. A novel aniline derivative from Peganum harmala L. promoted apoptosis via activating PI3K/Akt/mTOR-mediated autophagy in non-small cell lung cancer cells [J]. Int J Mol Sci, 2023, 24(16): 12626.
Peng Y, Wang Y Y, Zhou C, et al. PI3K/Akt/mTOR pathway and its role in cancer therapeutics: Are we making headway? [J]. Front Oncol, 2022, 12: 819128.
Shen W T, Luo P, Sun Y Q, et al. NRBF2 regulates the chemoresistance of small cell lung cancer by interacting with the p62 protein in the autophagy process [J]. iScience, 2022, 25(6): 104471.
王佳恩, 殷子喻, 马莉, 等. 灯盏乙素抗肿瘤作用机制研究进展[J]. 中草药, 2024, 55(13): 4608-4621.
Li J R, Sun M X, Tang M, et al. Mechanism of PI3K/Akt-mediated mitochondrial pathway in obesity-induced apoptosis (Review) [J]. Biomed Rep, 2024, 22(3): 40.
Rosa N, Speelman-Rooms F, Parys J B, et al. Modulation of Ca²⁺ signaling by antiapoptotic Bcl-2 versus Bcl-xL: From molecular mechanisms to relevance for cancer cell survival [J]. Biochim Biophys Acta Rev Cancer, 2022, 1877(6): 188791.
Pugazhenthi S, Nesterova A, Sable C, et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein [J]. J Biol Chem, 2000, 275(15): 10761-10766.
Wu Y H, Wang Y P, Liu H, et al. Correction: Mechanism of apoptosis in oral squamous cell carcinoma promoted by cardamonin through PI3K/Akt signaling pathway [J]. Sci Rep, 2025, 15: 35209.
Zhang X N, Sai B Q, Wang F, et al. Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT [J]. Mol Cancer, 2019, 18(1): 40.
Xu H, Wang J, Al-Nusaif M, et al. CCL2 promotes metastasis and epithelial-mesenchymal transition of non-small cell lung cancer via PI3K/Akt/mTOR and autophagy pathways [J]. Cell Prolif, 2024, 57(3): e13560.
Bai J, Kwok W C, Thiery J P. Traditional Chinese medicine and regulatory roles on epithelial-mesenchymal transitions [J]. Chin Med, 2019, 14(1): 34.
Peng F, Xu Q S, Jing X M, et al. GPX2 promotes EMT and metastasis in non-small cell lung cancer by activating PI3K/Akt/mTOR/Snail signaling axis [J]. FASEB BioAdvances, 2023, 5(6): 233-250.
Yuan R, Fan Q M, Liang X W, et al. Cucurbitacin B inhibits TGF-β1-induced epithelial-mesenchymal transition (EMT) in NSCLC through regulating ROS and PI3K/Akt/mTOR pathways [J]. Chin Med, 2022, 17(1): 24.
Nam M W, Kim C W, Choi K C. Epithelial-mesenchymal transition-inducing factors involved in the progression of lung cancers [J]. Biomol Ther, 2022, 30(3): 213-220.
Yu J T, Huo Q F, Duan X X. KDM6B regulates the tumor microenvironment and promotes EMT via the PI3K/Akt/ mTOR signaling in differentiated thyroid cancer [J]. BLOCELL, 2026, 50(4): 9.
Wang Z X. Cell cycle progression and synchronization: An overview [J] Methods Mol Biol, 2022, 2579: 3-23.
Thamjamrassri P, Ariyachet C. Circular RNAs in cell cycle regulation of cancers [J]. Int J Mol Sci, 2024, 25(11): 6094.
Qiu L, Gao Q, Liao Y H, et al. Targeted inhibition of the PTEN/PI3K/Akt pathway by YSV induces cell cycle arrest and apoptosis in oral squamous cell carcinoma [J]. J Transl Med, 2025, 23(1): 145.
Hong M, Zhu H, Liu W K, et al. Scoparone suppresses proliferation and cell cycle of hepatocellular carcinoma cells via inhibiting Akt/GSK-3β/cyclin D1 signaling pathway [J]. Transl Cancer Res, 2025, 14(3): 1638-1650.
魏文海, 李兴芳, 赵琼, 等. PI3K/Akt/mTOR信号通路抗非小细胞肺癌的机制及中药干预研究进展[J]. 中国实验方剂学杂志, 2023, 29(23): 218-226.
Zhou L X, Li M P, Chai Z B, et al. Anticancer effects and mechanisms of astragaloside-IV (Review) [J]. Oncol Rep, 2022, 49: 5.
Mokhfi F, Amin M, Zehravi M, et al. Alkaloid-based modulators of the PI3K/Akt/mTOR pathway for cancer therapy: Understandings from pharmacological point of view [J]. Chem Biol Interact, 2024, 402, 111218.
Wang T, Chen S, Wang Z L, et al. KIRREL promotes the proliferation of gastric cancer cells and angiogenesis through the PI3K/Akt/mTOR pathway [J]. J Cell Mol Med, 2024, 28(1): e18020.
Zhu Y Q, Lu Y X, Zhu Y F, et al. ST2L promotes VEGFA-mediated angiogenesis in gastric cancer by activating TRAF6/PI3K/Akt/NF-κB pathway via IL-33[J]. Sci Rep, 2024, 26393.
El-Tanani M, Nsairat H, Aljabali A A, et al. Role of mammalian target of rapamycin (mTOR) signalling in oncogenesis [J]. Life Sci, 2023, 323: 121662.
Gao Y X, E G, Feng L, et al. AMT inhibits the progression of non-small cell lung cancer by suppressing the PI3K/ Akt/GSK-3β/β-catenin pathway via H3K27me3 regulation [J]. Eur J Pharmacol, 2026, 1011, 178460.
Huang J, Wang C C, Hou Y X, et al. Molecular mechanisms of Thrombospondin-2 modulates tumor vasculogenic mimicry by PI3K/Akt/mTOR signaling pathway [J]. Biomed Pharmacother, 2023, 167: 115455.
Li L L, Zhao T, Hu Y L, et al. Mathematical modelling and bioinformatics analyses of drug resistance for cancer treatment [J]. Curr Bioinform, 2024, 19(3): 211-221.
Entezari M, Ghanbarirad M, Taheriazam A, et al. Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling [J]. Biomed Pharmacother, 2022, 150: 112963.
Lim Z F, Ma P C. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy [J]. J Hematol Oncol, 2019, 12(1): 134.
Singh B, Patwardhan R S, Jayakumar S, et al. Oxidative stress associated metabolic adaptations regulate radioresistance in human lung cancer cells [J]. J Photochem Photobiol B Biol, 2020, 213: 112080.
Xu L M, Yu H, Yuan Y J, et al. Overcoming of radioresistance in non-small cell lung cancer by microRNA-320a through HIF1α-suppression mediated methylation of PTEN [J]. Front Cell Dev Biol, 2020, 8: 553733.
Tan S M, Yi P, Wang H R, et al. RAC1 involves in the radioresistance by mediating epithelial-mesenchymal transition in lung cancer [J]. Front Oncol, 2020, 10: 649.
Wang W, Jia S N, Fan S F, et al. Dihydrotanshinone enhances the anticancer effects of sorafenib on hepatocellular carcinoma by inhibiting Akt signaling pathway activation [J]. Prog Biochem Biophys, 2024, 51(6): 1445-1457.
Gremke N, Polo P, Dort A, et al. mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability [J]. Nat Commun, 2020, 11: 4684.
Rascio F, Spadaccino F, Rocchetti M T, et al. The pathogenic role of PI3K/Akt pathway in cancer onset and drug resistance: An updated review [J]. Cancers, 2021, 13(16): 3949.
Glaviano A, Lau H S, Carter L M, et al. Harnessing the tumor microenvironment: Targeted cancer therapies through modulation of epithelial-mesenchymal transition [J]. J Hematol Oncol, 2025, 18(1): 6.
Ye Z L, Zeng D Q, Zhou R, et al. Tumor microenvironment evaluation for gastrointestinal cancer in the era of immunotherapy and machine learning [J]. Front Immunol, 2022, 13: 819807.
Desai S A, Patel V P, Bhosle K P, et al. The tumor microenvironment: Shaping cancer progression and treatment response [J]. J Chemother, 2025, 37(1): 15-44.
Bilotta M T, Antignani A, Fitzgerald D J. Managing the TME to improve the efficacy of cancer therapy [J]. Front Immunol, 2022, 13: 954992.
房传赐, 钱亚云. 斑蝥酸钠注射液靶向PI3K/Akt/ mTOR信号通路对人肺腺癌细胞A549迁移能力的影响[J]. 中医学报, 2021, 36(9): 1954-1958.
Liu Y P, Li L, Xu L, et al. Cantharidin suppresses cell growth and migration, and activates autophagy in human non-small cell lung cancer cells [J]. Oncol Lett, 2018, 15(5): 6527-6532.
Cheng G, Li L, Li Q, et al. β-Elemene suppresses tumor metabolism and stem cell-like properties of non-small cell lung cancer cells by regulating PI3K/Akt/mTOR signaling [J]. Am J Cancer Res, 2022 12(4): 1535-1555.
Liu J, Hu X J, Jin B, et al. β-Elemene induces apoptosis as well as protective autophagy in human non-small-cell lung cancer A549 cells [J]. J Pharm Pharmacol, 2012, 64(1): 146-153.
李琳, 成光宇, 李庆杰, 等. β-榄香烯对非小细胞肺癌细胞迁移的影响及其机制研究[J]. 世界科学技术—中医药现代化, 2021, 23(10): 3571-3577.
Lee J H, Chinnathambi A, Ali Alharbi S, et al. Farnesol abrogates epithelial to mesenchymal transition process through regulating Akt/mTOR pathway [J]. Pharmacol Res, 2019, 150: 104504.
孙卉, 陈晓静, 刘丽, 等. 双氢青蒿素通过PI3K/Akt通路逆转肺癌顺铂耐药A549/DDP细胞的分子机制[J]. 中国药师, 2021(6): 1013-1017.
Zeng W W, Xia L. Mechanistic of artemisinin extracts modulating cisplatin resistance in lung cancer A549/DDP cells via the PI3K/Akt pathway [J]. International J Pharmacology, 2025, 21(2): 217-230.
Zhang S Y, Li X B, Hou S G, et al. Cedrol induces autophagy and apoptotic cell death in A549 non-small cell lung carcinoma cells through the P13K/Akt signaling pathway, the loss of mitochondrial transmembrane potential and the generation of ROS [J]. Int J Mol Med, 2016, 38(1): 291-299.
Li Q S, Liu Y X, Zhang L, et al. Cedrol impedes lung cancer metastasis by reducing tumor-associated macrophage polarization mediated by Myc-driven aerobic glycolysis [J]. Hum Cell, 2025, 38(6): 177.
曹雪婷, 吴博雅, 陈静. 刺五加苷B介导PI3K/Akt/ mTOR通路诱导肺癌细胞凋亡和自噬[J]. 中国中药杂志, 2023, 48(24): 6693-6701.
Sun L H, Yuan W X, Wen G L, et al. Parthenolide inhibits human lung cancer cell growth by modulating the IGF-1R/PI3K/Akt signaling pathway [J]. Oncol Rep, 2020, 44(3): 1184-1193.
Mohiuddin M D, Kasahara K. Paclitaxel impedes EGFR-mutated PC9 cell growth via reactive oxygen species-mediated DNA damage and EGFR/PI3K/Akt/mTOR signaling pathway suppression [J]. Cancer Genomics Proteomics, 2021, 18(5): 645-659.
Lee Y C, Lin H H, Hsu C H, et al. Inhibitory effects of andrographolide on migration and invasion in human non-small cell lung cancer A549 cells via down-regulation of PI3K/Akt signaling pathway [J]. Eur J Pharmacol, 2010, 632(1/2/3): 23-32.
胡明亮. 基于HnRNPA2/B1-PI3K/Akt信号通路研究雷公藤甲素抗非小细胞肺癌的分子机制[D]. 宜春: 宜春学院, 2021.
Ren J K, Zhao S W, Lai J Y. Triptolide restrains the growth, invasion, stemness, and glycolysis of non-small cell lung cancer cells by PFKFB2-mediated PI3K/Akt pathway [J]. Chem Biol Drug Des, 2024, 103(1): e14450.
林小红. 雷公藤氯内酯醇对人肺腺癌裸鼠移植瘤的生长抑制及细胞自噬的机制研究[D]. 福州: 福建医科大学, 2019.
Kim S A, Kang O H, Kwon D Y. Cryptotanshinone induces cell cycle arrest and apoptosis of NSCLC cells through the PI3K/Akt/GSK-3β pathway [J]. Int J Mol Sci, 2018, 19(9): 2739.
Zhang J T, Wen G L, Sun L H, et al. Cryptotanshinone inhibits cellular proliferation of human lung cancer cells through downregulation of IGF-1R/PI3K/Akt signaling pathway [J]. Oncol Rep, 2018, 40(5): 2926-2934.
Jiang Y X, Bi Y L, Zhou L J, et al. Tanshinone IIA inhibits proliferation and migration by downregulation of the PI3K/Akt pathway in small cell lung cancer cells [J]. BMC Complementary Med Ther, 2024, 24(1): 68.
Wang T, Zou J, Wu Q, et al. Tanshinone II_A derivatives induced S-phase arrest through stabilizing c-Myc G-quadruplex DNA to regulate ROS-mediated PI3K/Akt/ mTOR pathway [J]. Eur J Pharmacol, 2021, 912: 174586.
Liao X Z, Gao Y, Huang S, et al. Tanshinone II_A combined with cisplatin synergistically inhibits non-small-cell lung cancer in vitro and in vivo via down-regulating the phosphatidylinositol 3-kinase/Akt signalling pathway [J]. Phytother Res, 2019, 33(9): 2298-2309.
Chen F J, Xiang W Q, Qiang G L. Tanshinone II_A affects the proliferation of A549/Tax by affecting the expression of MMP7 through the PI3K-Akt-mTOR signaling pathway [J]. Discov Oncol, 2025, 16(1): 369.
Zhao L Q, Zhang J N, Fan Y K, et al. Antiproliferative activity of carnosic acid is mediated via inhibition of cell migration and invasion, and suppression of phosphatidylinositol 3-kinases (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway [J]. Med Sci Monit, 2019, 25: 7864-7871.
Wang X Y, Wang Y J, Hou Z L, et al. Ingenane-type diterpenoids inhibit non-small cell lung cancer cells by regulating SRC/PI3K/Akt pathway [J]. Nat Prod Res, 2024, 38(19): 3460-3465.
Zhang D, Deng T, Yuan W, et al. Glaucocalyxin A induces apoptosis of non-small cell lung carcinoma cells by inhibiting the PI3K/Akt/GSK3β pathway [J]. Clin Exp Pharma Physio, 2022, 49(8): 797-804.
乌兰图雅, 刘艳萍, 于淼, 等. 熊果酸对肺癌A549细胞增殖、凋亡与侵袭的影响及可能机制[J]. 解剖科学进展, 2021, 27(6): 736-738.
李姝叶, 毕小菁, 王文军. 熊果酸对人非小细胞肺癌细胞系A549增殖、迁移、侵袭能力的影响及其机制探讨[J]. 山东医药, 2019, 59(15): 15-19.
Wang W D, Liu Y, Su Y, et al. Antitumor and apoptotic effects of cucurbitacin a in A-549 lung carcinoma cells is mediated via G₂/M cell cycle arrest and m-TOR/PI3K/Akt signalling pathway [J]. Afr J Tradit Complement Altern Med, 2017, 14(2): 75-82.
Yuan R, Fan Q M, Liang X W, et al. Cucurbitacin B inhibits TGF-β1-induced epithelial-mesenchymal transition (EMT) in NSCLC through regulating ROS and PI3K/Akt/mTOR pathways [J]. Chin Med, 2022, 17(1): 24.
Zhang J F, Aray B, Zhang Y, et al. Synergistic effect of cucurbitacin E and myricetin on anti-non-small cell lung cancer: Molecular mechanism and therapeutic potential [J]. Phytomedicine, 2023, 111: 154619.
Zhu X Q, Huang H, Zhang J, et al. The anticancer effects of cucurbitacin I inhibited cell growth of human non-small cell lung cancer through PI3K/Akt/p70S6K pathway [J]. Mol Med Report, 2017, 17(2):2750-2756.
沈佳伟, 顾春艳, 褚菲菲, 等. 人参皂苷Rg₂调控PI3K/Akt通路逆转非小细胞肺癌顺铂耐药的分子机制研究[J]. 当代医药论丛, 2025, 23(18): 1-3.
韩宁, 李秋实, 王鑫洋, 等. 人参皂苷Rg₃抑制肺癌细胞增殖和侵袭的作用及机制[J]. 中国临床药理学杂志, 2023, 39(20): 2942-2945.
Li J L, Yang B. Ginsenoside Rg₃ enhances the radiosensitivity of lung cancer A549 and H1299 cells via the PI3K/Akt signaling pathway [J]. Vitro Cell Dev Biol Anim, 2023, 59(1): 19-30.
Xie Q P, Wen H K, Zhang Q, et al. Inhibiting PI3K-Akt signaling pathway is involved in antitumor effects of ginsenoside Rg₃ in lung cancer cell [J]. Biomed Pharmacother, 2017, 85: 16-21.
Yu X L, Wang Q H, Dai Z X. Ginsenosides inhibit the proliferation of lung cancer cells and suppress the rate of metastasis by modulating EGFR/VEGF signaling pathways [J]. J Oleo Sci, 2024, 73(2): 219-230.
Song C, Yuan Y, Zhou J, et al. Network pharmacology-based prediction and verification of ginsenoside Rh₂-induced apoptosis of A549 cells via the PI3K/Akt pathway [J]. Front Pharmacol, 2022, 13: 878937.
Du N, Song D L, Sun X, et al. Ginsenoside Rk1 inhibits the malignant progression of lung cancer by inactivating the INSR/PI3K/Akt pathway [J]. Tissue Cell, 2025, 95: 102880.
Chen Q, Wang M, Shen C J. Bauerane induces S-phase cell cycle arrest, apoptosis, and inhibition of proliferation of A549 human lung cancer cells through the phosphoinositide 3-kinase (PI3K)/Akt and signal transducer and activator of transcription 3(STAT3) signaling pathway [J]. Med Sci Monit, 2020, 26: e919558.
陈苏红. 柴胡皂苷D通过抑制PI3K/Akt/mTOR通路促进肺腺癌A549细胞自噬和凋亡的机制研究[D]. 合肥: 安徽医科大学, 2023.
Xia J B, Dai L J, Wang L S, et al. Ganoderic acid DM induces autophagic apoptosis in non-small cell lung cancer cells by inhibiting the PI3K/Akt/mTOR activity [J]. Chem Biol Interact, 2020, 316: 108932.
Zhao R L, Chen M J, Jiang Z Q, et al. Platycodin-D induced autophagy in non-small cell lung cancer cells via PI3K/Akt/mTOR and MAPK signaling pathways [J]. J Cancer, 2015, 6(7): 623-631.
Seo Y S, Kang O H, Kong R, et al. Polygalacin D induces apoptosis and cell cycle arrest via the PI3K/Akt pathway in non-small cell lung cancer [J]. Oncol Rep, 2018, 39(4):1702-1710.
Liu Y, Xia X C, Meng L Y, et al. Alisol B₂₃-acetate inhibits the viability and induces apoptosis of non-small cell lung cancer cells via PI3K/Akt/mTOR signal pathway [J]. Mol Med Report, 2019, 20(2):1187-1195.
He W, Li X, Xia S Y. Lupeol triterpene exhibits potent antitumor effects in A427 human lung carcinoma cells via mitochondrial mediated apoptosis, ROS generation, loss of mitochondrial membrane potential and downregulation of m-TOR/PI3K/Akt signalling pathway [J]. J BUON, 2018 23(3): 635-640.
李紫瑞. 黄芪甲苷逆转非小细胞肺癌A549/DDP细胞顺铂耐药的作用机制研究[D]. 南京: 南京中医药大学, 2022.
Xing Y, Xue W W, Teng Y H, et al. Raddeanin A promotes autophagy-induced apoptosis by inactivating PI3K/Akt/ mTOR pathway in lung adenocarcinoma cells [J]. Naunyn Schmiedeberg’s Arch Pharmacol, 2023, 396(9): 1987-1997.
王子健, 庄作会, 刘春霞. 积雪草酸通过调控PI3K/ Akt/mTOR信号通路抑制A549细胞的增殖和迁移[J]. 中国老年学杂志, 2021, 41(21): 4827-4830.
Zhang L L, Man S L, Wang Y S, et al. Paris saponin II induced apoptosis via activation of autophagy in human lung cancer cells [J]. Chem Biol Interact, 2016, 253: 125-133.
He H, Xu C, Zheng L, et al. Polyphyllin VII induces apoptotic cell death via inhibition of the PI3K/Akt and NF-κB pathways in A549 human lung cancer cells [J]. Mol Med Report, 2019, 21(2):597-606.
Chen M Z, Li J, Hu S D, et al. Jujuboside B inhibits the proliferation and migration of non-small cell lung cancer H1299 cells through inhibiting PI3K/Akt and Wnt/β-catenin pathways [J]. Cancer Manag Res, 2025, 17: 1143-1153.

2026年第57卷第10期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.10.031

接收时间：2025-11-03
首发时间：2026-09-09

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2025-11-03

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.10.031

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT